// App-Quantinova.ai

3822 : Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study

Researchers

Presenter

  • Sarit Assouline

Principal Investigators

  • Evangelos Briasoulis

  • Yoo-Hong Min

  • Maria Diez-Campelo

  • Alexandr Myasnikov

  • Frank Mannino

  • Yasser Mostafa Kamel

  • Conrad Messam

  • Nicole L. Stone

  • Geoffrey W. Chan

  • Arancha Alonso

  • Regina Garcia Delgado

  • Peter -Gorman

  • Hyeoung Joon Kim

  • Sung-Soo Yoon

  • Andrey Zaritskey

  • Catherine M. Flynn

Medical Centers

  • Hospital Virgen de la Victoria, Malaga, Spain

  • Division of Hematology and Department of Oncology, Jewish General Hospital, Montreal, QC, Canada

  • State Healthcare Institution, Republican Hospital named after V.A. Baranov, Petrozavodsk, Russia

  • Saint James's Hospital, Dublin, Ireland

  • Hospital Universitario Quiron Madrid, Madrid, Spain

  • Almazov Centre for Heart, Blood & St. Petersburg, Russia

  • Hematology, Hospital Clinico Universitario de Salamanca-IBSAL, Salamanca, Spain

  • Department of Hematology, University of Ioannina School of Medicine, Ioannina, Greece

  • Tel Aviv University, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

  • Cork University Hospital, Cork, Ireland

Locations

  • Ireland

  • Canada

  • Greece

  • Spain

  • Israel

  • Russia

Companies

  • GlaxoSmithKline plc.

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Myelodysplastic Syndrome

  • Immune thrombocytopenia

  • Acute myelocytic leukemia

  • Thrombocytopenia

  • Sepsis

Biomarkers

  • Alanine transaminase

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Eltrombopag

  • Hydroxyurea

  • Hydroxycarbamide

Outcome

  • N/A


Study Design

  • open label

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim